In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal ...

IDRx’s lead candidate IDRX-42 is being investigated in a Phase I/IIb trial in patients with advanced gastrointestinal stromal ...

This morning, the UK pharma group confirmed it had signed an agreement to buy privately-held IDRx for $1 billion upfront, ...

The British pharma giant announced plans to acquire IDRx, a Plymouth-based biotech working on precision treatments for ...

GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will ...

GSK (NYSE:GSK) finalized the deal to acquire Boston-based, clinical-stage biopharmaceutical company—IDRx for a total of up to ...

GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early ...

Is the frenzy of JPM dealmaking finally underway? GSK announced Monday morning that it will acquire the privately-held ...

GSK (GSK) and IDRx announced that they have entered into an agreement under which GSK will acquire IDRx. Under the agreement, GSK will pay $1B ...

LONDON — Seeking to build up its cancer business, GSK said Monday it is buying the privately held U.S. biotech IDRx for $1 billion upfront. The deal, which includes another $150 million in ...

The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.

Boston-based biotechnology firm developing therapy for treatment of gastrointestinal stromal tumors - Anadolu Ajansı ...